

A2

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
3 January 2003 (03.01.2003)

PCT

(10) International Publication Number  
**WO 03/000878 A2**

(51) International Patent Classification?: C12N 9/90

(21) International Application Number: PCT/EP02/06957

(22) International Filing Date: 24 June 2002 (24.06.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
01 115 225.3 22 June 2001 (22.06.2001) EP  
01 120 939.2 31 August 2001 (31.08.2001) EP

(71) Applicant (for DE only): ROCHE DIAGNOSTICS GMBH [DE/DE]; Sandhofer Strasse 116, 68305 Mannheim (DE).

(71) Applicant (for all designated States except DE): F.HOFF-MANN-LA ROCHE AG [CH/CH]; Grenzacherstr. 124, CH-4070 Basel (CH).

(72) Inventors: SCHOLZ, Christian; Sindelsdorfer Strasse 35a, 82377 Penzberg (DE). ANDRES, Herbert; Kapellwiese 39, 82377 Penzberg (DE). FAATZ, Elke; Steinkreuz 1, 82386 Huglfing (DE). ENGEL, Alfred; Kustermannstrasse 3a, 82327 Tutzing (DE). SCHMITT,

Urban; Waldstrasse 36, 82386 Oberhausen (DE). BAZARSUREN, Ariuna; Birkenstrasse 29, 82377 Penzberg (DE). SCHAARSHCIMIDT, Peter; Birkenstrasse 4, 82390 Eberling (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GI1, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF FKBP CHAPERONES AS EXPRESSION TOOL

**WO 03/000878 A2**(57) Abstract: The present invention relates to the cloning and expression of foreign protein or polypeptides in bacteria such as *Escherichia coli*. In particular, this invention relates to expression tools comprising a FKBP-type peptidyl prolyl isomerase selected from the group consisting of FkpA, SlyD, and trigger factor, methods of recombinant protein expression, the recombinant polypeptides thus obtained as well as to the use of such polypeptides.

BEST AVAILABLE COPY

42

### Use of FKBP chaperones as expression tool

The present invention relates to the cloning and expression of a heterologous protein or polypeptide in bacteria such as *Escherichia coli*. In particular, this invention relates to expression tools comprising a FKBP-type peptidyl prolyl isomerase selected from the group consisting of FkpA, SlyD, and trigger factor, methods of recombinant protein expression,

- 5 the recombinant polypeptides thus obtained as well as to the use of such polypeptides.

A large variety of expression systems has been described in the patent as well as in the scientific literature. However, despite the fact that fusion proteins have become a cornerstone of modern biology, obtaining the target protein in a soluble, biologically active form, as well as in high yield, continues to be a major challenge (Kapust, R. B. and Waugh,

- 10 D. S., Protein Sci 8 (1999) 1668-74).

Examples of fusion partners that have been touted as solubilizing agents include thioredoxin (TRX), glutathione S-transferase (GST), maltose-binding protein (MBP), Protein A, ubiquitin, and DsbA. Although widely recognized and potentially of great importance, this solubilizing effect remains poorly understood. It is not clear, for example,

- 15 what characteristics besides intrinsically high solubility epitomize an effective solubilizing agent. Are all soluble fusion partners equally proficient at this task, or are some consistently more effective than others? Similarly, it is not known whether the solubility of many different polypeptides can be improved by fusing them to a highly soluble partner or whether this approach is only effective in a small fraction of cases.

- 20 The state of the art relating to the most potent expression systems has recently been summarized by Kapust et al., *supra*. In their attempt to produce soluble fusion proteins comprising various target proteins they assessed three different and prominent candidate fusion partners. Maltose-binding protein (MBP), glutathione S-transferase (GST), and thioredoxin (TRX) have been tested for their ability to inhibit the aggregation of six diverse  
25 proteins that normally accumulate in an insoluble form. All these candidate expression systems are known to the skilled artisan and described in detail elsewhere (e.g., EP 293 249 describes in detail the use of GST as an expression tool).

- Remarkably, Kapust et al., *supra*, found that MBP is a far more effective solubilizing agent than the other two fusion partners also widely used in the art. Moreover, they  
30 demonstrated that only in some cases fusion to MBP can promote the proper folding of the attached protein into its biologically active conformation.

It is especially critical that many aggregation-prone polypeptides may be rendered soluble by fusing them to an appropriate partner, but that some candidate fusion partners in a more or less unpredictable way are much better solubilizing agents than others.

While working on the recombinant expression of several retroviral surface glycoproteins 5 (rsgps), we investigated the utility of many expression tools as known and recommended in the art, e.g. by Kapust et al., *supra*. However, we found that all the expression systems tested did suffer from one or several of the following shortcomings: low yield, fusion polypeptide difficult to handle, or insolubility of the fusion protein at physiological buffer conditions.

A great demand therefore exists to provide for alternative, efficient expression tools, which 10 are especially appropriate for the recombinant expression of aggregation prone proteins, e.g. like the rsgps.

There is a wealth of patent literature relating to proteins which bind to the immunosuppressant FK-506, the so-called FK-506 binding proteins or FKBP's.

These proteins have been extensively studied and commercial applications have been 15 designed centering around the FK-506 binding activity of these proteins. For example, WO 93/25533 makes use of CTP: CMP-3-deoxy-D-manno-octulosonate cytidyl transferase (=CKS) as expression tool. A FKBP is inserted into a CKS-based expression vector downstream of the CKS gene. The fusion protein obtained is used to improve measurements of FK-506 and other immunosuppressants.

20 WO 00/28011 discloses materials and methods for regulation of biological events such as target gene transcription and growth, proliferation and differentiation of engineered cells.

WO 97/10253 relates to a high throughput assay for screening of compounds capable of binding to a fusion protein which consists of a target protein and an FK-506-binding protein. Disclosed is the use of a FKBP12-Src homology (SH2) fusion protein in an high 25 throughput screening assay. The fusion protein is produced in soluble form in the bacterial periplasm and released by standard freeze-thaw treatment.

It was the task of the present invention to investigate whether it is possible to develop and provide efficient alternative expression systems which can be used for improved expression of a recombinant protein comprising a rsgp as a target protein and which at the same time 30 are also appropriate for less critical target proteins.

To our surprise we have been able to identify certain modular members of the FKBP-type family of the peptidyl prolyl isomerase (PPI or PPIase) chaperones as very promising cloning tools. We found that an expression system based on a FKBP-type family of the chaperone selected from the group consisting of SlyD, FkpA, and trigger factor is ideal to express critical proteins like an rsgp and at the same time we could also demonstrate that these chaperones as well represent extremely promising cloning tools for less critical target proteins.

Summary of the invention

The present invention in a first embodiment relates to a recombinant DNA molecule, 10 encoding a fusion protein, comprising at least one nucleotide sequence coding for a target polypeptide and upstream thereto at least one nucleotide sequence coding for a FKBP chaperone, characterized in that the FKBP chaperone is selected from the group consisting of FkpA, SlyD and trigger factor.

Preferred ways of designing such recombinant DNA molecules as well as their use as part of 15 an expression vector, a host cell comprising such expression vector, and in the production of fusion polypeptide are also disclosed.

It has in addition been found that the recombinant fusion polypeptides themselves exhibit surprising and advantageous properties, e.g. with regard to solubilization, purification and handling. In a further embodiment the present invention relates to a recombinantly 20 produced fusion protein comprising at least one polypeptide sequence corresponding to a FKBP chaperone selected from the group consisting of FkpA, SlyD and trigger factor and at least one polypeptide sequence corresponding to a target peptide.

A further embodiment relates to a recombinantly produced fusion protein comprising at least one polypeptide sequence corresponding to a FKBP chaperone selected from the 25 group consisting of FkpA, SlyD and trigger factor, at least one polypeptide sequence corresponding to a target polypeptide, and at least one peptidic linker sequence of 10 - 100 amino acids.

Preferred recombinant fusion polypeptides are also disclosed as well as the use of such fusion polypeptides in various applications.

Description of the Figures**Figure 1** UV spectrum of FkpA-gp41 at pH 2.5

UV-spectrum of the fusion polypeptide FkpA-gp41 after dialysis against 50 mM sodium phosphate, pH 2.5; 50 mM NaCl. Surprisingly, the two-domain construct 5 remains completely soluble after removal of the solubilizing chaotropic agent GuHCl. There is no evidence for the existence of light-straying aggregates that would be expected to cause a baseline drift and significant apparent absorption at wavelengths beyond 300 nm.

**Figure 2** Near UV CD spectrum of FkpA-gp41 at pH 2.5

The spectrum was recorded on a Jasco 720 spectropolarimeter in 20 mM sodium 10 phosphate, pH 2.5; 50 mM NaCl at 20°C and was accumulated nine times to lower the noise. Protein concentration was 22.5  $\mu$ M at a path length of 0.5 cm. The aromatic ellipticity shows the typical signature of gp41. At pH 2.5, FkpA is largely unstructured and does not contribute to the signal in the Near-UV-CD at all.

**Figure 3** Far UV CD spectrum of FkpA-gp41 at pH 2.5

15 The spectrum was recorded on a Jasco 720 spectropolarimeter in 20 mM sodium phosphate pH 2.5; 50 mM NaCl at 20°C and was accumulated nine times to improve the signal-to-noise ratio. Protein concentration was 2.25  $\mu$ M at a path-length of 0.2 cm. The minima at 220 and 208 nm point to a largely helical structure of gp41 in the context of the fusion protein. The spectral noise below 197 nm is due to the high amide absorption and 20 does not report on any structural features of the fusion protein. Nevertheless, the typical helix-maximum at 193 nm can be guessed.

**Figure 4** Near UV CD of FkpA-gp41 under physiological buffer conditions.

The spectrum was recorded on a Jasco 720 spectropolarimeter in 20 mM sodium phosphate, pH 7.4; 50 mM NaCl at 20°C and was accumulated nine times to lower the 25 noise. Protein concentration was 15.5  $\mu$ M at a path-length of 0.5 cm. Strikingly, the aromatic ellipticity of the covalently linked protein domains of g41 and FkpA (continuous line) is made up additively from the contributions of native-like all-helical gp41 at pH 3.0 (lower dashed line) and the contributions of FkpA at pH 7.4 (upper dashed line). This indicates that the carrier FkpA and the target gp41 (i.e. two distinct functional folding

- 5 -

units) refold reversibly and quasi-independently when linked in a polypeptide fusion protein.

Figure 5 Far UV CD of FkpA-gp41 under physiological buffer conditions.

The spectrum was recorded on a Jasco 720 spectropolarimeter in 20 mM Sodium phosphate, pH 7.4; 50 mM NaCl at 20°C and accumulated nine times to improve the signal-to-noise ratio. Protein concentration was 1.55 µM at a path-length of 0.2 cm. The strong signals at 222 nm and 208 nm, respectively, point to a largely helical structure of gp41 in the context of the fusion construct. The noise below 198 nm is due to the high protein absorption and does not reflect any secondary structural properties of FkpA-gp41.

10 Figure 6 The Near-UV-CD-spectra of scFkpA and scSlyD resemble each other

CD spectra were recorded on a Jasco-720 spectropolarimeter in 0.5 cm-cuvettes and averaged to improve the signal-to-noise-ratio. Buffer conditions were 50 mM sodium phosphate pH 7.8, 100 mM sodium chloride at 20 °C. Protein concentration was 45 µM for both scFkpA (top line at 280 nm) and scSlyD (lower line at 280 nm), respectively. The 15 structural similarity of both proteins is evidenced by the similar signature in the „fingerprint region“.

Detailed description

The present invention describes novel polypeptide expression systems. In a preferred embodiment it relates to a recombinant DNA molecule, encoding a fusion protein, 20 comprising at least one nucleotide sequence coding for a target polypeptide and upstream thereto at least one nucleotide sequence coding for a FKBP chaperone, characterized in that the FKBP chaperone is selected from the group consisting of FkpA, SlyD and trigger factor.

As the skilled artisan will appreciate the term "at least one" is used to indicate that one or more nucleotide sequences coding for a target polypeptide, or for a FKBP chaperone, 25 respectively, may be used in construction of a recombinant DNA molecule without departing from the scope of the present invention. Preferably the DNA construct will comprise one or two sequences coding for a target polypeptide, one being most preferred, and at the same time will contain at least one and at most four sequences coding for a chaperone, one or two being most preferred.

- The term "recombinant DNA molecule" refers to a DNA molecule which is made by the combination of two otherwise separated segments of sequence accomplished by the artificial manipulation of isolated segments of polynucleotides by genetic engineering techniques or by chemical synthesis. In so doing one may join together polynucleotide segments of desired functions to generate a desired combination of functions.

Large amounts of the polynucleotides may be produced by replication in a suitable host cell. Natural or synthetic DNA fragments coding for proteins or fragments thereof will be incorporated into recombinant polynucleotide constructs, typically DNA constructs, capable of introduction into and replication in a prokaryotic or eukaryotic cell.

- 10 The polynucleotides may also be produced by chemical synthesis, including, but not limited to, the phosphoramidite method described by Beaucage, S. L. and Caruthers, M. H., Tetrahedron Letters 22 (1981) 1859-1862 and the triester method according to Matteucci, M. D. and Caruthers, M. H., J. Am. Chem. Soc. 103 (1981) 3185-3191. A double-stranded fragment may be obtained from the single-stranded product of chemical synthesis either by  
15 synthesizing the complementary strand and annealing the strands together under appropriate conditions or by adding the complementary strand using DNA polymerase with an appropriate primer sequence.

A polynucleotide is said to "encode" a polypeptide if, in its native state or when manipulated by methods known in the art, the polynucleotide can be transcribed and/or  
20 translated to produce the polypeptide or a fragment thereof.

- A target polypeptide according to the present invention may be any polypeptide required in larger amounts and therefore difficult to isolate or purify from other non-recombinant sources. Examples of target proteins preferably produced by the present methods include mammalian gene products such as enzymes, cytokines, growth factors, hormones, vaccines,  
25 antibodies and the like. More particularly, preferred overexpressed gene products of the present invention include gene products such as erythropoietin, insulin, somatotropin, growth hormone releasing factor, platelet derived growth factor, epidermal growth factor, transforming growth factor  $\alpha$ , transforming growth factor  $\beta$ , epidermal growth factor, fibroblast growth factor, nerve growth factor, insulin-like growth factor I, insulin-like  
30 growth factor II, clotting Factor VIII, superoxide dismutase,  $\alpha$ -interferon,  $\gamma$ -interferon, interleukin-1, interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, granulocyte colony stimulating factor, multi-lineage colony stimulating activity, granulocyte-macrophage stimulating factor, macrophage colony stimulating factor, T cell

- growth factor, lymphotoxin and the like. Preferred overexpressed gene products are human gene products. Moreover, the present methods can readily be adapted to enhance secretion of any overexpressed gene product which can be used as a vaccine. Overexpressed gene products which can be used as vaccines include any structural, membrane-associated, 5 membrane-bound or secreted gene product of a mammalian pathogen. Mammalian pathogens include viruses, bacteria, single-celled or multi-celled parasites which can infect or attack a mammal. For example, viral vaccines can include vaccines against viruses such as human immunodeficiency virus (HIV), vaccinia, poliovirus, adenovirus, influenza, hepatitis A, hepatitis B, dengue virus, Japanese B encephalitis, Varicella zoster, 10 cytomegalovirus, hepatitis A, rotavirus, as well as vaccines against viral diseases like measles, yellow fever, mumps, rabies, herpes, influenza, parainfluenza and the like. Bacterial vaccines can include vaccines against bacteria such as *Vibrio cholerae*, *Salmonella typhi*, *Bordetella pertussis*, *Streptococcus pneumoniae*, *Hemophilus influenza*, *Clostridium tetani*, *Corynebacterium diphtheriae*, *Mycobacterium leprae*, *R. rickettsii*, *Shigella*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Coccidioides immitis*, *Borellia burgdorferi*, and the like.
- 15

Preferably, the target protein is a member of a group consisting of HIV-1 gp41, HIV-2 gp36, HTLV gp21, HIV-1 p17, SlyD, FkpA, and trigger factor.

- A target polypeptide according to the present invention may also comprise sequences, e.g., 20 diagnostically relevant epitopes, from several different proteins constructed to be expressed as a single recombinant polypeptide.

The folding helpers termed peptidyl prolyl isomerases (PPIs or PPIases) are subdivided into three families, the parvulines (Schmid, F. X., Molecular chaperones in the life cyle of proteins (1998) 361-389, Eds. A. L. Fink and Y. Goto, Marcel Decker In., New York), Rahfeld, J. U., et al., FEBS Lett 352 (1994) 180-4) the cyclophilines (Fischer, G., et al., 25 Nature 337 (1989) 476-8, and the FKBP family (Lane, W. S., et al., J Protein Chem 10 (1991) 151-60). The FKBP family exhibits an interesting biochemical feature since its members have originally been identified by their ability to bind to macrolides, e.g., FK 506 and rapamycin (Kay, J. E., Biochem J 314 (1996) 361-85).

According to the present invention the preferred modular PPIases are FkpA (Ramm, K. 30 and Pluckthun, A., J Biol Chem 275 (2000) 17106-13), SlyD (Hottenrott, S., et al., J Biol Chem 272 (1997) 15697-701) and trigger factor (Scholz, C., et al., Embo J 16 (1997) 54-8), all members of the FKBP family. Most preferred are the chaperones FkpA and SlyD.

It is also well known and appreciated that it is not necessary to always use the complete sequence of a molecular chaperone. Functional fragments of chaperones (so-called modules) which still possess the required abilities and functions may also be used (cf. WO 98/13496).

- 5 For instance, FkpA is a periplasmic PPI that is synthesized as an inactive precursor molecule in the bacterial cytosol and translocated across the cytoplasmic membrane. The active form of FkpA (mature FkpA or periplasmic FkpA) lacks the signal sequence (amino acids 1 to 25) and thus comprises amino acids 26 to 270 of the precursor molecule. Relevant sequence information relating to FkpA can easily be obtained from public 10 databases, e.g., from "SWISS-PROT" under accession number P 45523. The FkpA used as expression tool according to the present invention lacks the N-terminal signal sequence.

A close relative of FkpA, namely SlyD, consists of a structured N-terminal domain responsible for catalytic and chaperone functions and of a largely unstructured C-terminus that is exceptionally rich in histidine and cysteine residues (Hottenrott, supra). We found 15 that a C-terminally truncated variant of SlyD comprising amino acids 1-165 exerts exceptionally positive effects on the efficient expression of target proteins. Unlike in the wild-type SlyD, the danger of compromising disulfide shuffling is successfully circumvented in the truncated SlyD-variant (1-165) used. A recombinant DNA molecule comprising a truncated SlyD (1-165) represents a preferred embodiment of the present 20 invention.

In a preferred mode of designing a DNA construct according to the present invention no signal peptides are included. The expression systems according to the present invention have been found most advantageous when working as cytosolic expression system. This cytosolic expression results in the formation of inclusion bodies. Different from the 25 pronounced and well-known problems usually associated with inclusion bodies, we now have found that not only an exceptionally high amount of protein is produced, but that the recombinant proteins according to the present invention are also easy to handle, e.g. easy to solubilize and to refold. In a preferred embodiment the present invention thus relates to a recombinant DNA molecule, encoding a fusion protein, comprising at least one nucleotide 30 sequence coding for a target polypeptide and upstream thereto at least one nucleotide sequence coding for a FKBP chaperone, wherein the FKBP chaperone is selected from the group consisting of FkpA, SlyD and trigger factor further characterized in that the DNA construct lacks a signal peptide.

The term "lacks a signal peptide" must not be understood as an undue limitation. As the skilled artisan will readily appreciate either the construct may in fact lack the signal peptide sequence. As an alternative, however, the sequence may simply be modified to lack signal peptide function.

- 5 Variants of the above-discussed chaperones, bearing one or several amino acid substitutions or deletions, may also be used to obtain a recombinant DNA or a fusion polypeptide according to the present invention. The skilled artisan can easily assert whether such variants, e.g., fragments or mutants of chaperones or chaperones from alternative sources, are appropriate for a method of the invention by using the procedures as described  
10 in the Examples section.

The term "recombinant" or "fusion polypeptide" as used in the present invention, refers to a polypeptide comprising at least one polypeptide domain corresponding to the FKBP-chaperone used as expression tool and at least one polypeptide domain corresponding to the target protein. Optionally such fusion protein may additionally comprise a linker 15 polypeptide of 10 – 100 amino acid residues. As the skilled artisan will appreciate such linker polypeptide is designed as most appropriate for the intended application, especially in terms of length, flexibility, charge, and hydrophilicity.

- Preferably the DNA construct of the present invention encodes a fusion protein comprising a polypeptide linker in between the polypeptide sequence corresponding to the FKBP-chaperone and the polypeptide sequence corresponding to the target protein. Such DNA sequence coding for a linker in addition to e.g., provide for a proteolytic cleavage site, may also serve as a polylinker, i.e., it may provide multiple DNA restriction sites to facilitate fusion of the DNA fragments coding for a target protein and a chaperone domain.

- The present invention makes use of recombinant DNA technology in order to construct appropriate DNA molecules.

- In a further preferred embodiment the present invention relates a recombinant DNA molecule, encoding a fusion protein, comprising operably linked at least one nucleotide sequence coding for a target polypeptide and upstream thereto at least one nucleotide sequence coding for a FKBP chaperone, characterized in that the FKBP chaperone is selected from the group consisting of FkpA, SlyD and trigger factor.

Polynucleotide sequences are operably linked when they are placed into a functional relationship with another polynucleotide sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects transcription or expression of the coding sequence. Generally, operably linked means that the linked sequences are 5 contiguous and, where necessary to join two protein coding regions, both contiguous and in reading frame. However, it is well known that certain genetic elements, such as enhancers, may be operably linked even at a distance, i.e., even if not contiguous.

As the skilled artisan will appreciate it is often advantageous to design a nucleotide sequence coding for a fusion protein such that one or a few, e.g., up to nine, amino acids 10 are located in between the two polypeptide domains of said fusion protein. Fusion proteins thus constructed, as well as the DNA molecules encoding them obviously are also within the scope of the present invention.

DNA constructs prepared for introduction into a host typically comprise a replication system recognized by the host, including the intended DNA fragment encoding the desired 15 target fusion peptide, and will preferably also include transcription and translational initiation regulatory sequences operably linked to the polypeptide encoding segment. Expression systems (expression vectors) may include, for example, an origin of replication or autonomously replicating sequence (ARS) and expression control sequences, a promoter, an enhancer and necessary processing information sites, such as ribosome- 20 binding sites, RNA splice sites, polyadenylation sites, transcriptional terminator sequences, and mRNA stabilizing sequences.

The appropriate promoter and other necessary vector sequences are selected so as to be functional in the host. Examples of workable combinations of cell lines and expression vectors include but are not limited to those described Sambrook, J., et al., in "Molecular 25 Cloning: A Laboratory Manual" (1989) -, Eds. J. Sambrook, E. F. Fritsch and T. Maniatis, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, or Ausubel, F., et al., in "Current protocols in molecular biology" (1987 and periodic updates), Eds. F. Ausubel, R. Brent and K. R.E., Wiley & Sons Verlag, New York; and Metzger, D., et al., Nature 334 (1988) 31-6. Many useful vectors for expression in bacteria, yeast, mammalian, insect, plant 30 or other cells are known in the art and may be obtained from vendors including but not limited to Stratagene, New England Biolabs, Promega Biotech, and others. In addition, the construct may be joined to an amplifiable gene (e.g., DHFE) so that multiple copies of the gene may be obtained.

Expression and cloning vectors will likely contain a selectable marker, a gene encoding a protein necessary for the survival or growth of a host cell transformed with the vector, although such a marker gene may be carried on another polynucleotide sequence co-introduced into the host cell. Only those host cells expressing the marker gene will survive and/or grow under selective conditions. Typical selection genes include but are not limited to those encoding proteins that (a) confer resistance to antibiotics or other toxic substances, e.g. ampicillin, tetracycline, etc.; (b) complement auxotrophic deficiencies; or (c) supply critical nutrients not available from complex media. The choice of the proper selectable marker will depend on the host cell, and appropriate markers for different hosts are known in the art.

The vectors containing the polynucleotides of interest can be introduced into the host cell by any method known in the art. These methods vary depending upon the type of cellular host, including but not limited to transfection employing calcium chloride, rubidium chloride, calcium phosphate, DEAE-dextran, other substances, and infection by viruses. Large quantities of the polynucleotides and polypeptides of the present invention may be prepared by expressing the polynucleotides of the present invention in vectors or other expression vehicles in compatible host cells. The most commonly used prokaryotic hosts are strains of *Escherichia coli*, although other prokaryotes, such as *Bacillus subtilis* may also be used. Expression in *Escherichia coli* represents a preferred mode of carrying out the present invention.

Construction of a vector according to the present invention employs conventional ligation techniques. Isolated plasmids or DNA fragments are cleaved, tailored, and religated in the form desired to generate the plasmids required. If desired, analysis to confirm correct sequences in the constructed plasmids is performed in a known fashion. Suitable methods for constructing expression vectors, preparing in vitro transcripts, introducing DNA into host cells, and performing analyses for assessing expression and function are known to those skilled in the art. Gene presence, amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA, dot blotting (DNA or RNA analysis), or in situ hybridization, using an appropriately labeled probe which may be based on a sequence provided herein. Those skilled in the art will readily envisage how these methods may be modified, if desired.

In a preferred embodiment a recombinant DNA molecule according to the present invention comprises a single nucleotide sequence coding for a FKBP-chaperone selected

from the group consisting of FkpA, SlyD, and trigger factor and a single nucleotide sequence coding for a target polypeptide.

A fusion protein comprising two FKBP-chaperone domains and one target protein domain is also very advantageous. In a further preferred embodiment the recombinant DNA 5 molecule according to the present invention comprises two sequences coding for a FKBP-chaperone and one sequence coding for a target polypeptide.

The DNA molecule may be designed to comprise both the DNA sequences coding for the FKBP-chaperone upstream to the target protein. Alternatively the two FKBP-domains may be arranged to sandwich the target protein. The construct comprising both FKBP-domains 10 upstream to the target protein represents a preferred embodiment according to the present invention.

The DNA construct comprising two chaperone domains as well as a target polypeptide domain preferably also contains two linker peptides in between these domains. In order to allow for a systematic cloning the nucleotide sequences coding for these two linker peptide 15 sequences preferably are different. This difference in nucleotide sequence must not necessarily result in a difference in the amino-acid sequence of the linker peptides. In yet a further preferred embodiment the amino acid sequences of the two linker peptides are identical. Such identical linker peptide sequences for example are advantageous if the fusion protein comprising two FKBP-chaperone domains as well as their target protein 20 domain is to be used in an immunoassay.

In cases where it is desired to release one or all of the chaperones out of a fusion protein according to the present invention the linker peptide is constructed to comprise a proteolytic cleavage site. A recombinant DNA molecule encoding a fusion protein comprising at least one polypeptide sequence coding for a target polypeptide, upstream 25 thereto at least one nucleotide sequence coding for a FKBP-chaperone selected from the group consisting of FkpA, SlyD, and trigger factor and additionally comprising a nucleic acid sequence coding for a peptidic linker comprising a proteolytic cleavage site, represents a further embodiment of this invention.

An expression vector comprising operably linked a recombinant DNA molecule according 30 to the present invention, i.e., a recombinant DNA molecule encoding a fusion protein comprising at least one polynucleotide sequence coding for a target polypeptide and upstream thereto at least one nucleotide sequence coding for a FKBP-chaperone, wherein

- 13 -

the FKBP-chaperone is selected from FkpA, SlyD, and trigger factor, has proven to be very advantageous.

The expression vector comprising a recombinant DNA according to the present invention may be used to express the fusion protein in a cell free translation system or may be used to

- 5 transform a host cell. In a preferred embodiment the present invention relates to a host cell transformed with an expression vector according to the present invention.

In a further preferred embodiment the present invention relates to a method of producing a fusion protein. Said method comprising the steps of culturing a host cell transformed with an expression vector according to the present invention, expression of that fusion 10 protein in the respective host cell and purification of said fusion protein.

As discussed above the FKBP-chaperone domain of FkpA, SlyD, or trigger factor, respectively, is naturally or artificially constructed to yield a cytosolic fusion polypeptide expression. The fusion protein thus produced is obtained in form of inclusion bodies. Whereas in the art tremendous efforts are spent to obtain any desired recombinant protein 15 or the fusion protein directly in a soluble form, we have found that the fusion protein according to the present invention is easily obtained in soluble form from inclusion bodies. In a further preferred embodiment the present invention therefore relates to a method of producing a fusion protein according to the steps described above, wherein said fusion protein is purified from inclusion bodies.

- 20 The purification of fusion protein from inclusion bodies is easily achieved and performed according to standard procedures known to the skilled artisan, like chaotropic solubilization and various ways of refolding.

Isolation and purification of the fusion protein starts from solubilizing buffer conditions, i.e. from a buffer wherein the inclusion bodies, i.e., the fusion protein, are/is solubilized. An 25 appropriate buffer, which may be termed "non-physiological" or "solubilizing" buffer has to meet the requirement that both the target protein and the FKBP chaperone are not irreversibly denatured. Starting from such buffer conditions, the chaperone is in close proximity to the target protein, and a change of the buffer conditions from non-physiological to physiological conditions is possible without precipitation of the fusion 30 protein.

- An appropriate (non-physiological) buffer, i.e., a buffer wherein both the target protein which is essentially insoluble and the PPI-chaperone are soluble either makes use of high or low pH, or of a high chaotropic salt concentration or of a combination thereof. The solubilizing buffer preferably is a buffer with rather a high concentration of a chaotropic salt, e.g., 6.0 M guanidinium chloride at a pH of about 6. Upon renaturation both the target protein as well as the chaperone assume their native-like structure and the chaperone exerts its positive solubilizing effect..

In the context of this invention physiological buffer conditions are defined by a pH value between 5.0 and 8.5 and a total salt concentration below 500 mM, irrespective of other non-salt ingredients that optionally may be present in the buffer (e.g. sugars, alcohols, detergents) as long as such additives do not impair the solubility of the fusion protein comprising the target protein and the chaperone.

A variety of target proteins has been expressed in large amounts.

- The expression system according to the present invention, for example, has been shown to work extremely well with biochemically rather different target proteins, e.g. SlyD, FkpA (proteins which are readily soluble), HIV-1 p17 (a protein which is difficult to express in high amounts using conventional expression systems), HTLV gp21 (a protein which tends to aggregate), and HIV-1 gp41, as well as HIV-2 gp36 (both proteins are extremely prone to aggregation and essentially insoluble under physiological buffer conditions). As can be easily gathered from Example 4 specifically relating to these proteins the efficient expression systems according to the present invention work and result in high levels of fusion protein produced. Similar positive findings have been made with a variety of other target proteins expressed as a fusion protein according to the present invention.

From the list of positive example it becomes readily obvious that the novel expression system as disclosed in the present invention, provide for extremely attractive universal expression systems.

- The expression systems as disclosed herein also have been compared to standard expression systems making use of carrier proteins as recommended in the art, like MBP. It has been found that the novel systems with the target polypeptides tested are quite advantageous.
- The relative yield of fusion protein produced according to the present invention was at least as good and in the majority of cases even higher as compared to the relative yield using MBP-based expression. Efficacy of expression can be assessed both in terms of yield of

- 15 -

fusion protein, e.g., per g of *E. coli* cell mass or on a molar basis, comparing the concentrations of a target protein comprised in different fusion proteins.

- The present invention in a preferred embodiment relates to a recombinantly produced fusion protein comprising at least one polypeptide sequence corresponding to a FKBP chaperone selected from the group consisting of FkpA, SlyD and trigger factor and at least one polypeptide sequence corresponding to a target peptide.

It has been found that the fusion proteins according to the present invention exhibit advantageous properties, thus e.g., facilitating production, handling and use of otherwise critical proteins. This becomes readily obvious from the description of the positive results obtained with a fusion protein comprising HIV-1 gp41. Whereas recombinantly produced gp41 itself is essentially insoluble, it is readily soluble if present as part of a fusion protein according to the present invention.

- In general a protein is considered "essentially insoluble" if in a buffer consisting of 20 mM sodium phosphate pH 7.4, 150 mM NaCl it is soluble in a concentration of 50 nM or less. A fusion protein according to the present invention comprising a FKBP chaperone and a target protein is considered "soluble" if under physiological buffer conditions, e. g., in a buffer consisting of 20 mM sodium phosphate pH 7.4, 150 mM NaCl the target protein comprised in the PPI-chaperone complex is soluble in a concentration of 100 nM or more.

We found that the recombinantly produced fusion protein according to the present invention can be readily obtained from inclusion bodies in soluble form, even if the target protein is an aggregation prone protein like HIV-1 gp41. A striking feature of gp41 comprised in a recombinantly produced FkpA-gp41 is its exceptional solubility at physiological buffer conditions as compared to the "unchaperoned" gp41 ectodomain.

- Moreover, it has been possible to demonstrate that the target protein comprised in a fusion protein according to the present invention readily can be obtained in a native-like structure. Such native-like structure, e.g., for HIV-1 gp41 has been confirmed by Near-UV-CD or by its immunoreactivity. Near-UV-CD analysis has shown the typical "gp41-signature" which is known to the skilled artisan.

The fusion protein according to the present invention also is very easy to handle, e.g., it is quite easy to renature such fusion protein. It is interesting that the "chaotropic material" (i.e. FkpA-gp41 in 6.0-7.0 M GuHCl) can be refolded in different ways, all resulting in a

thermodynamically stable and soluble native-like form. Refolding is achieved at high yields, both by dialysis and by rapid dilution, as well as by renaturing size exclusion chromatography or matrix-assisted refolding. These findings suggest that in this covalently linked form, the gp41-FkpA fusion polypeptide is a thermodynamically stable rather than a

5 metastable protein.

Some of the FKBP-chaperones (e.g. FkpA) exert their chaperone function in form of oligomers, i.e., in a complex comprising two or more noncovalently associated FKBP polypeptides. We have surprisingly found that it is possible to design and produce such an active FKBP-dimer as a single fusion protein on one and the same polypeptide. We have  
10 termed these constructs single-chain PPIs, or single-chain FKBP. The single-chain PPI comprising two SlyD domains therefore is termed scSlyD and the single-chain PPI comprising two FkpA domains therefore is termed scFkpA. A single-chain peptidyl-prolyl-isomerase, i.e. a fusion protein comprising two PPI-domains represents a very advantageous and therefore preferred embodiment of the present invention. The sc-PPI  
15 according to the present invention may be a parvuline, a cyclophiline or a FKBP. The sc-PPIs selected from the FKBP family of chaperones are preferred. Most preferred are sc SlyD and Sc FkpA, respectively.

A recombinantly produced fusion protein comprising at least one polypeptide sequence corresponding to a FKBP chaperone selected from the group consisting of FkpA, SlyD and  
20 trigger factor, at least one polypeptide sequence corresponding to a target polypeptide, and at least one peptidic linker sequence of 10 - 100 amino acids represents a further preferred embodiment of the present invention.

As the skilled artisan will appreciate the peptidic linker may be constructed to contain the amino acids which are most appropriate for the required application. E.g., in case of a  
25 hydrophobic target protein the linker polypeptide preferably will contain an appropriate number of hydrophilic amino acids. The present invention specifically also relates to fusion proteins which comprise the target polypeptide and one, or two FKBP-chaperones or chaperone domains and an appropriate peptidic linker sequences between domains. For such applications where the target protein is required in free form a linker peptide or linker  
30 peptides are used, which contain an appropriate proteolytic cleavage site. Peptide sequences appropriate for proteolytic cleavage are well-known to the skilled artisan and comprise amongst others, e.g., Ile-Glu-Gly-Arg, cleaved at the carboxy side of the arginine residue by coagulation factor Xa, or Gly-Leu Pro-Arg-Gly-Ser, a thrombin cleavage site, etc..

- As mentioned above the fusion proteins according to the present invention can easily be obtained from inclusion bodies following a simple refolding scheme. They are readily soluble and target polypeptides comprised in such fusion proteins can easily be obtained in native-like confirmation. This is quite advantageous for polypeptides derived from an infectious organism because such native-like polypeptides are most advantageous in diagnostic as well as in therapeutic applications. In a preferred embodiment the fusion protein according to the present invention is further characterized in that a target protein is a polypeptide of interest as known from an infectious organism. Preferred infectious organisms according to the present invention are HIV, HTLV, and HCV.
- 10 From the scientific as well as from the patent literature it is well-known which peptide sequences contain diagnostically relevant epitopes. For the skilled artisan it is nowadays no problem to identify such relevant epitopes. In a further preferred embodiment the target protein corresponding to a polypeptide derived from an infectious organism will contain at least one diagnostically relevant epitope.
- 15 Due to their advantageous properties the recombinantly produced fusion proteins according to the present invention in further preferred embodiments are used for the immunization of laboratory animals, in the production of a vaccine or in an immunoassay, respectively.
- In case a therapeutic application of the novel fusion proteins is intended, preferably a  
20 composition comprising a recombinantly produced fusion protein according to the present invention and a pharmaceutically acceptable excipient will be formulated.
- The following examples, references, sequence listing and figures are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without  
25 departing from the spirit of the invention.
- Examples**
- Example 1 Recombinant production of HIV-1 gp41 using an FkpA-based expression system**
- 30 1.1 Construction of an expression plasmid comprising FkpA and gp41

Wild-type FkpA was cloned, expressed and purified according to Bothmann and Plückthun, *J Biol Chem* 275 (2000) 17106-17113 with some minor modifications. For storage, the protein solution was dialyzed against 20 mM NaH<sub>2</sub>PO<sub>4</sub>/NaOH (pH 6.0), 100 mM NaCl and concentrated to 26 mg/ml (1 mM).

- 5 For cytosolic expression, the FkpA-coding sequence of the above expression vector was modified to lack the sequence part coding for the signal peptide and to comprise instead only the coding region of mature FkpA.

In the first step, the restriction site *Bam*HI in the coding region of the mature *E. coli* FkpA was deleted using the QuikChange site-directed mutagenesis kit of Stratagene (La Jolla, CA;

- 10 USA) with the primers:

5'-gcgggttgtccggatcccaccgaattc-3' (SEQ ID NO: 1)

5'-gaattcggtggatacccggaacaccgcg-3' (SEQ ID NO: 2)

The construct was named EcFkpA(Δ *Bam*HI)[GGGS]<sub>3</sub>.

- 15 HIV-1 gp41 (535-681)-His<sub>6</sub> was cloned and expressed in a T7 promotor-based expression system. The gene fragment encoding amino acids 535-681 from HIV-1 envelope protein was amplified by PCR from the T7-based expression vector using the primers:

5'-cgggatccgtggcggttcaggcggtggctctggtggcggtacgcgtg-acggtagccggcag-3' (SEQ ID NO: 3)

5'-ccgctcgagggtaccacagccaaatttttat-3' (SEQ ID NO: 4)

- 20 The fragment was inserted into EcFkpA(Δ *Bam*HI)[GGGS]<sub>3</sub> using *Bam*HI and *Xba*I restriction sites.

The codons for a glycine-serine-rich linker [GGGS]<sub>3</sub> between FkpA and e-gp41 were inserted with reverse primer for cloning of FkpA and with forward primer for cloning of e-gp41.

- 25 The resulting construct was sequenced and found to encode the desired protein. Variants of this protein have also been generated by site-directed mutagenesis according to standard procedures. A variant of gp41 comprising four amino acid substitutions as compared to the

- 19 -

wild-type sequence is, e.g. encoded by the DNA-constructs of SEQ ID NO: 5 and 6, making use of FkpA or SlyD as expression system, respectively.

### 1.2 Purification of the FkpA-gp41 fusion protein from *E. coli* cells

*E. coli* BL21 cells harboring the expression plasmid were grown to a OD<sub>600</sub> of 0.7, and 5 cytosolic overexpression was induced by adding 1 mM of IPTG at a growth temperature of 37°C. Four hours after induction, the cells were harvested by centrifugation (20 min at 5000 g). The bacterial pellet was resuspended in 50 mM sodium phosphate pH 7.8, 6.0 M GuHCl (guanidinium chloride), 5 mM imidazole and stirred at room temperature (10 min) for complete lysis. After repeated centrifugation (Sorvall SS34, 20000 rpm, 4°C), the 10 supernatant was filtered (0.8/0.2 µm) and applied to a Ni-NTA-column (NTA: Nitrilotriacetate; Qiagen; Germantown, MD), pre-equilibrated in lysis buffer. Unspecifically bound proteins were removed in a washing step by applying 10 column volumes of lysis buffer. Finally, the bound target protein was eluted with 50 mM sodium phosphate, pH 2.5, 6.0 M GuHCl, and was collected in 4 ml fractions. The absorbance was 15 recorded at 280 nm.

The resulting acidic and chaotropic solution may be stored at 4°C for further purification steps or *in vitro* refolding experiments.

Starting with this unfolded material, different refolding methods, such as dialysis, rapid dilution, renaturing size exclusion chromatography or matrix-assisted refolding can be 20 used and carried out successfully, all of them leading to virtually the same native-like folded and soluble protein.

### 1.3 Renaturation by dialysis and rapid dilution

Material, solubilized as described above, is transferred into physiological buffer conditions by dialysis. The chosen cut-off value of the dialysis tubing was 4000 – 6000 Daltons.

25 To induce refolding of the ectodomain (the HIV-1 gp41 part of the fusion protein), GuHCl was removed from the eluted protein by dialysis against 50 mM sodium phosphate, pH 2.5, 50 mM NaCl (sodium chloride). It is well known that the isolated ectodomain is all-helical and forms tertiary contacts at this extreme pH. When analyzing recombinantly produced FkpA by means of near UV CD, it was found that FkpA is essentially unstructured under 30 the same conditions. It is surprising that refolding of gp41-FkpA by dialysis results in a

readily soluble protein complex comprising the covalently linked gp41 and FkpA protein domains. The UV spectrum (Figure 1) lacks stray light, *i.e.*, apparent absorption beyond 300 nm. Stray light would be indicative of aggregates, thus the spectrum shown in Figure 1 implies that the re-folded material does not contain significant amounts of aggregates.

- 5 Circular dichroism spectroscopy (CD) is the method of choice to assess both secondary and tertiary structure in proteins. Ellipticity in the aromatic region (260-320 nm) reports on tertiary contacts within a protein (*i.e.*, the globular structure of a regularly folded protein), whereas ellipticity in the amide region reflects regular repetitive elements in the protein backbone, *i.e.*, secondary structure.
- 10 The near UV CD spectrum shown in Figure 2 provides compelling evidence that the ectodomain (in the context of the fusion protein) displays native-like tertiary contacts at pH 2.5. The spectrum of the covalently linked gp41/FkpA protein domains almost coincides with the spectrum of the isolated ectodomain under identical conditions (data not shown). The typical signature of gp41 was found: a maximum of ellipticity at 290 nm,
- 15 a characteristic shoulder at 285 nm and another maximum at 260 nm reflecting an optically active disulfide bridge. It is important to note that FkpA does not contribute to the near UV signal at all under the respective conditions. In fact, the aromatic ellipticity of FkpA at pH 2.5 virtually equals the baseline (data not shown).

In agreement with the results from the near UV region, the far UV CD of the fusion 20 construct at pH 2.5 points to a largely structured gp41 molecule. The two maxima at 220 nm and 208 nm make up, and correspond to, the typical signature of an all-helical ectodomain (Figure 3). From the conditions indicated (50 mM sodium phosphate, pH 2.5, 50 mM NaCl), the FkpA-gp41 fusion polypeptide can easily be transferred to physiological buffer conditions by rapid dilution. In conclusion, both near and far UV CD underline that 25 native-like structured gp41 is available (in the context of the fusion protein also containing FkpA) in a very convenient fashion.

#### 1.4 Renaturation by size exclusion chromatography (SEC)

Unfolded gp41-FkpA polypeptide (dissolved in 50 mM sodium phosphate, pH 7.8, 7.0 M GuHCl) was applied onto a Superdex 200 gel filtration column equilibrated with 20 mM 30 sodium phosphate, pH 7.4, 50 mM NaCl, 1 mM EDTA. FkpA-gp41 elutes essentially in three main fractions: as a high molecular associate, as an apparent hexamer species and as

an apparent trimer species. The apparent trimer fraction was concentrated and assessed for its tertiary structure in a near UV CD measurement (Figure 4).

- The resulting graph is virtually an overlay curve to which both the carrier protein FkpA and the target protein gp41 contribute in a 1:1 ratio. Most fortunately, gp41 displays tertiary  
5 structure at neutral pH and is evidently solubilized by the covalently bound chaperone. In other words, the chaperone FkpA seems to accept the native-like structured ectodomain gp41 as a substrate and to solubilize this hard-to-fold protein at a neutral working pH. Thus, a crucial requirement for producing high amounts of soluble gp41 antigen for diagnostic purposes is fulfilled.
- 10 The far UV CD of FkpA-gp41 at pH 7.4 (Figure 5) confirms the near UV CD results in that it shows the additivity of the signal contributions of FkpA and gp41, respectively. As expected, the spectrum is dominated by the highly helical gp41 ectodomain (maximal ellipticity at 220 nm and 208 nm, respectively).

15 The data obtained with the covalently linked gp41/FkpA protein domains solubilized at pH 7.4 under the conditions mentioned above indicate that FkpA and gp41 behave as independently folding units within the polypeptide construct.

#### Example 2 Use of a SlyD-based expression vector

The chaperone SlyD has been isolated by routine cloning procedures from *E. coli*. For recombinant expression a DNA construct has been prepared coding for amino acids 1 to  
20 165 of SlyD. An expression vector has been constructed comprising SlyD(1-165) as fusion partner and HIV-1 gp41 as target protein (cf.: SEQ ID NO: 6). The fusion protein was expressed and successfully purified as described for FkpA-gp41 above. Interestingly, we found that a native-like fusion polypeptide of the SlyD(1-165)-gp41 type can be obtained in a very convenient manner by dialysis of the chaotropic material (dissolved, e.g. in 7.0 M GuHCl) against 50 mM sodium phosphate pH 7.4, 150 mM NaCl at room temperature.

#### Example 3 Purification of scFkpA and scSlyD

The single-chain PPIases scSlyD (SEQ ID NO: 7) and scFkpA (SEQ ID NO: 8), respectively, were obtained from an *E. coli* overproducer according to virtually the same  
30 purification protocol as described in Example 1. In short: the induced cells were harvested, washed in PBS and lysed in 50 mM sodium phosphate pH 7.8, 100 mM sodium chloride,

7.0 M GuHCl at room temperature. The unfolded target proteins were bound to a Ni-NTA-column via their C-terminal hexa-His-tag and were refolded in 50 mM sodium phosphate pH 7.8, 100 mM sodium chloride. After this matrix-assisted refolding procedure, the proteins were eluted in an imidazole gradient and subjected to a gel 5 filtration on a Superdex 200® column.

Alternatively, scSlyD and scFkpA may be dialysed after elution to remove residual concentrations of imidazole. Both proteins turn out to be highly soluble. ScSlyD, for example, does not tend to aggregation at concentrations up to 25 mg/ml. In order to elucidate the tertiary structure of the refolded scPPIases, we monitored CD-spectra in the 10 Near-UV-region. The signatures of both scSlyD and scFkpA resemble each other and reflect the close relationship and thus structural homology of the two FKBPs. Due to the low content in aromatic residues, the signal intensity of scSlyD (Fig. 6) is, however, significantly lower than the one of scFkpA.

#### Example 4 Improved expression of target proteins

15 The biochemically quite different target proteins HIV-1 gp41, HIV-2 gp36, HIV-1 p17 and HTLV gp21 have been expressed using the pET/BL21 expression system either without fusion partner (gp41, gp36, p17, gp21) or using same standard expression system but comprising a DNA-construct coding for a fusion protein according to the present invention (SlyD-gp41, FkpA-gp41, FkpA-p17, SlyD-gp36, FkpA-gp21). The efficiency of 20 these systems has been compared in terms of yield of recombinant protein per *E. coli* cell mass [mg/g]. As becomes readily obvious from table 1, the novel expression systems lead to a significant improvement for all proteins tested.

Table 1:

Protein	Yield [mg protein/g E. coli cell mass]
gp41	~1-2
SlyD-gp41	~30
FkpA-gp41	~25
p17	~1
FkpA-p17	~15
gp36	~1-2
SlyD-gp36	~45
gp21	~4
FkpA-gp21	~30

List of References

- Sambrook, J., et al., in "Molecular Cloning: A Laboratory Manual" (1989) -, Eds. J. Sambrook, E. F. Fritsch and T. Maniatis, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, NY
- 5 Beaucage, S. L. and Caruthers, M. H., Tetrahedron Letters 22 (1981) 1859-1862  
Ausubel, F., et al., in "Current protocols in molecular biology" (1987 and periodic updates),  
Eds. F. Ausubel, R. Brent and K. R.E., Wiley & Sons Verlag, New York  
Fischer, G., et al., Nature 337 (1989) 476-8  
Hottenrott, S., et al., J Biol Chem 272 (1997) 15697-701
- 10 Kapust, R. B. and Waugh, D. S., Protein Sci 8 (1999) 1668-74  
Kay, J. E., Biochem J 314 (1996) 361-85  
Lane, W. S., et al., J Protein Chem 10 (1991) 151-60  
Matteucci, M. D. and Caruthers, M. H., J. Am. Chem. Soc. 103 (1981) 3185-3191  
Metzger, D., et al., Nature 334 (1988) 31-6
- 15 Rahfeld, J. U., et al., FEBS Lett 352 (1994) 180-4  
Ramm, K. and Pluckthun, A., J Biol Chem 275 (2000) 17106-13  
Schmid, F. X., Molecular chaperones in the life cyle of proteins (1998) 361-389, Eds. A. L.  
Fink and Y. Goto, Marcel Decker In., New York  
Scholz, C., et al., Embo J 16 (1997) 54-8
- 20 EP 293 249  
WO 00/28011  
WO 93/25533  
WO 97/10253
- 25 WO 98/1349

## Patent Claims

1. A recombinant DNA molecule, encoding a fusion protein, comprising at least one nucleotide sequence coding for a target polypeptide and upstream thereto at least one nucleotide sequence coding for a FKBP chaperone, characterized in that the FKBP chaperone is selected from the group consisting of FkpA, SlyD and trigger factor.
2. The recombinant DNA molecule according to claim 1 further characterized in that it comprises at least one nucleotide sequence coding for a peptidic linker of 10 - 100 amino acids located in between said sequence coding for the target polypeptide and said sequence coding for the FKBP chaperone.
- 10 3. A recombinant DNA molecule according to claim 1 or 2, comprising one nucleotide sequence coding for said FKBP chaperone.
4. A recombinant DNA molecule according to claim 1 or 2, comprising two sequences coding for a FKBP chaperone.
- 15 5. The recombinant DNA molecule of claim 4 further characterized in that the two sequences coding for a FKBP chaperone are located upstream of the sequence coding for the target polypeptide.
6. The recombinant DNA molecule of claim 4 further characterized in that one sequence coding for a PPI chaperone is located upstream of the target polypeptide and the other sequence coding for a PPI chaperone is located downstream of the sequence coding for the target peptide.
- 20 7. The recombinant DNA molecule according to claim 4 to 6, further characterized in that, it comprises two nucleic acid sequences coding for a linker polypeptide of 10 - 100 amino acids.
8. The recombinant DNA molecule according to claim 7, wherein the two nucleic acid sequences coding for a linker of 10 - 100 amino acids are different.
- 25 9. The recombinant DNA molecule according to any of claims 2 to 8, wherein at least one of said linker sequences codes for a polypeptide linker comprising a proteolytic cleavage site.

- 26 -

10. An expression vector comprising operably linked a recombinant DNA molecule according to any of claims 1- 9.
11. A host cell transformed with an expression vector according to claim 10.
12. A method of producing a fusion protein said method comprising the steps of
  - 5 a. culturing host cells according to claim 11
  - b. expression of said fusion protein and
  - c. purification of said fusion protein.
13. A recombinantly produced fusion protein comprising at least one polypeptide sequence corresponding to a FKBP chaperone selected from the group consisting of FkpA, SlyD and trigger factor and at least one polypeptide sequence corresponding to a target peptide.
- 10 14. A recombinantly produced fusion protein comprising at least one polypeptide sequence corresponding to a FKBP chaperone selected from the group consisting of FkpA, SlyD and trigger factor, at least one polypeptide sequence corresponding to a target polypeptide, and at least one peptidic linker sequence of 10 - 100 amino acids.
- 15 15. The fusion protein according to claim 13 or 14, further characterized in that, it comprises one polypeptide sequence corresponding to said FKBP chaperone.
16. The fusion protein according to claim 13 or 14, further characterized in that, it comprises two polypeptide sequences corresponding to said FKBP chaperone
- 20 17. The fusion protein according to claim 16, further characterized in that, said two FKBP chaperones are located N-terminal with respect to the target polypeptide.
18. The fusion protein according to claim 16, further characterized in that, one of said two FKBP chaperones is located N-terminal and one of said FKBP chaperones is located C-terminal to the target polypeptide.

19. A recombinantly produced fusion protein comprising at least one target polypeptide, two sequences corresponding to FKBP chaperones selected from the group consisting of FkpA, SlyD and trigger factor and two peptidic linker sequences of 10 - 100 amino acids.
- 5 20. The fusion protein according to claim 19, wherein at least one of said peptidic linker sequences comprises a proteolytic cleavage site.
21. The fusion protein according to any of claims 13 - 20, wherein said target protein comprises a polypeptide from an infectious organism.
- 10 22. The fusion protein according to claims 21, further characterized in that said polypeptide comprises at least one diagnostically relevant epitope of an infectious organism.
23. Use of a recombinantly produced fusion protein according to any of claims 13 - 22, for immunization of laboratory animals.
- 15 24. Use of a recombinantly produced fusion protein according to any of claims 13 - 22, in the production of a vaccine.
25. Use of a recombinantly produced fusion protein according to any of claims 13 - 22, in an immunoassay.
26. A composition comprising a recombinantly produced fusion protein according to any of claims 13 - 22, and a pharmaceutically acceptable excipient.



Figure 1:Figure 2





Figure 3Figure 4

Figure 5Figure 6

## Sequenzprotokoll

<110> Roche Diagnostics GmbH  
F. Hoffmann-La Roche AG

5 <120> Use of FKBP chaperones as expression tool

<130> 21306WO

10 <140>  
<141>

<150> EP01115225.3  
<151> 2001-06-22

15 <150> EP01120939.2  
<151> 2001-08-31

<160> 8

20 <170> PatentIn Ver. 2.1

<210> 1  
<211> 29

25 <212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:primer 1

30 <400> 1  
gccccgttgc cgggtatccc accgaattc 29

35 <210> 2  
<211> 29  
<212> DNA  
<213> Artificial Sequence

40 <220>  
<223> Description of Artificial Sequence:primer 2

<400> 2  
gaattccgttgc ggatacccgaaacaccgc 29

45 <210> 3  
<211> 61  
<212> DNA

50 <213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:primer 3

55 <400> 3

- 2 -

cgggatccgg tggcggttca ggcggtgtggct ctgggtggcgg tacgctgacg gtacaggcca 60  
g 61

5 <210> 4  
<211> 30  
<212> DNA  
<213> Artificial Sequence

10 <220>  
<223> Description of Artificial Sequence:primer 4

<400> 4  
ccgctcqagg taccacagcc aatttgttat

15 <210> 5  
<211> 1269  
<212> DNA  
20 <213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:coding for a  
EklmA-cm41 fusion protein

25 <400> 5  
 atggctgaag ctgcaaaaacc tgctacaact gctgacagca aagcagcgtt caaaaatgac 60  
 gatcagaataa cagcttatgc actgggtgct tcgctgggtc gttacatgg aaatcttcct 120  
 aaagaacaag aaaatccgg catcaactcg gataaaatgc agctgatcgc tggtgttcg 180  
 30 gatgcatttg ctgataaagg caaaactccg gaccaagaga tcgaacagac tctgcgaacga 240  
 ttcaagaatgc gctgttgcgtc ttctgcgtcg gcaagatgg aaaaagacgc ggctgtataac 300  
 gaagcaaaaag gttaaagatg ccggcagaaaa ttggccaaatgg agaaatgggt gaaaacctct 360  
 tcaatgttc tggttattca ggttagatgg cccgtttaaaa gccaagcacc gaaaagacgc 420  
 gatactgtt tagtgaacta caaaaggtaacg ctgatcgacg gtaaaagatgg cgacaaactt 480  
 35 tacacccgtg gttaaccggct ctctttccgt ctggcgggtt ttatccccgg ttggacacaga 540  
 ggtctgaaga acatcaaaagg aggccgttaag atcaaaatccgtt ttatccaccg aagaactggct 600  
 taacggcaag ccgggttccccc gggtatccca cggaaattcta ccctgggttt tgacgttagag 660  
 ctgtctggatg tgaacccagc gcccggatgt gatgcggaaatcc cggaaatggc tgccggaaatcc 720  
 40 gggatcttc cttaaaaaagg tggcggttcc ggcgggttgc ctgggttggcc atccgggtggc 780  
 ggttcccgcc tggtctctgg tggccgttacg ctgacgggtac aggccagaca attatgttt 840  
 ggtatagtgc agcagcggaa caatggatgtc agggctgttggccggaaatcc gcatctggag 900  
 caactcacag ttctggggccaa caagcggctc caggccaaagag aatccggatgtt gggaaatgatc 960  
 45 gctgtgcctt ggaatgtcttag ttggagatataa aatctctgg aacagatgg gaataaacatg  
 1080 acctggatgg agtggggacag agaaattaac aattacacaa gcttaataaca ttcccttaatt  
 1140 gaagaatgcg aaaaccagca agaaaaaaat gaacaagaat tattggattt agataaaatgg  
 50 1200 gcaatgttggt ggaattgggtt taacataaca aatccggatgtt ggtacactcgaa gcaccaccac  
 1260 caccaccac  
 1269

- 3 -

<210> 6  
 <211> 1026  
 <212> DNA  
 <213> Artificial Sequence  
**5**  
 <220>  
 <223> Description of Artificial Sequence:coding for a SlyD-gp41 fusion protein

**10** <400> 6  
 atgaaatgc caaaagacct ggtggtcagc ctggccatac aggtacgtac agaagacgg 60  
 gtgttggttg atgagtctcc ggtgagtgcg ccgtcgact acctgcattgg tcaacggttc 120  
 ctgtatctcg tggcgttaaaac ggcgcgtggaa ggtcatgaag ttggcgacaa atttgatgtc 180  
 gctgttggcc cgaacacgcg ttacgttcg taccacgaaa accttgtca acgtgttcc 240  
**15** aaagacgtat ttatggcggt tgatgaactg caggtaggtt tgcgtttccg ggctgaaacc 300  
 gaccagggtc cggttacccgt tgaatactt ccgggttgaag acgtatcaatgt ctgtgggtat 360  
 ggttaaccaca tgctggccgg tcagaacccgtt aaatttcaacgt ttgaatgtgtt ggccgattcgc 420  
 gaagcgtactg aagaagaact ggctcatgtt cacgttcacg ggcgcacacg tcaaccaccc 480  
 gatcacgacc acgacgggtgg cgggtccggc gttggctctg gtggcgatc cggtggcggt 540  
**20** tccggcggtg gctctgggtt cggtaatcgta acggtagcagg ccagacaattt atttgtctgg 600  
 atagtgcagc agcagaacaaa tgatgttgcgg gctatttgggg ccgcaacacgca tctggagcca 660  
 ctccacgtctt gggggccacaa gcagctcccg gcaagagaaac tggctgttggaa aagatactta 720  
 aaggatcaac agtctctggg gatgggggt tggctgttggaa aactcatttt caccactgtc 780  
 gtgccttggaa atgtctgttgg gtagataaaa tctctggaaac agatattggaa taacatgacc 840  
**25** tggtatgggtt gggacacggaa aattaacaat tacacaaatgtt taatacattt cttaaatggcc 900  
 gaatcgaaaa accaggcaaga aaaaatggaa caaagaattt tggatattttaaaaatggcc 960  
 agtttggaa attggtttaa cataacaaat tggctgttggt acctcgagca ccaccacacc  
**30** 1026  
 caccac  
**35** 1026

<210> 7  
 <211> 367  
 <212> PRT  
 <213> Artificial Sequence

**40** <220>  
 <223> Description of Artificial Sequence:single-chain  
 SlyD

**45** <400> 7  
 Met Lys Val Ala Lys Asp Leu Val Val Ser Leu Ala Tyr Gln Val Arg  
 1 5 10 15

Thr Glu Asp Gly Val Leu Val Asp Glu Ser Pro Val Ser Ala Pro Leu  
 20 25 30

Asp Tyr Leu His Gly His Ser Leu Ile Ser Gly Leu Glu Thr Ala  
 35 40 45

Leu Glu Gly His Glu Val Gly Asp Lys Phe Asp Val Ala Val Gly Ala  
 50 55 60

**55** Asn Asp Ala Tyr Gly Gln Tyr Asp Glu Asn Leu Val Gln Arg Val Pro  
 65 70 75 80

- 4 -

Lys Asp Val Phe Met Gly Val Asp Glu Leu Gln Val Gly Met Arg Phe  
85 90 95

5 Leu Ala Glu Thr Asp Gln Gly Pro Val Pro Val Glu Ile Thr Ala Val  
100 105 110

Glu Asp Asp His Val Val Val Asp Gly Asn His Met Leu Ala Gly Gln  
115 120 125

10 Asn Leu Lys Phe Asn Val Glu Val Val Ala Ile Arg Glu Ala Thr Glu  
130 135 140

Glu Glu Leu Ala His Gly His Val His Gly Ala His Asp His His His  
145 150 155 160

15 Asp His Asp His Asp Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly  
165 170 175

20 Ser Gly Gly Ser Gly Gly Ser Gly Gly Gly Lys Val Ala Lys  
180 185 190

Asp Leu Val Val Ser Leu Ala Tyr Gln Val Arg Thr Glu Asp Gly Val  
195 200 205

25 Leu Val Asp Glu Ser Pro Val Ser Ala Pro Leu Asp Tyr Leu His Gly  
210 215 220

His Gly Ser Leu Ile Ser Gly Leu Glu Thr Ala Leu Glu Gly His Gly  
225 230 235 240

30 Val Gly Asp Lys Phe Asp Val Ala Val Gly Ala Asn Asp Ala Tyr Gly  
245 250 255

35 Gln Tyr Asp Glu Asn Leu Val Gln Arg Val Pro Lys Asp Val Phe Met  
260 265 270

Gly Val Asp Glu Leu Gln Val Gly Met Arg Phe Leu Ala Glu Thr Asp  
275 280 285

40 Gln Gly Pro Val Pro Val Glu Ile Thr Ala Val Glu Asp Asp His Val  
290 295 300

Val Val Asp Gly Asn His Met Leu Ala Gly Gln Asn Leu Lys Phe Asn  
305 310 315 320

45 Val Glu Val Val Ala Ile Arg Glu Ala Thr Glu Glu Glu Leu Ala His  
325 330 335

50 Gly His Val His Gly Ala His Asp His His His Asp His Asp His Asp  
340 345 350

Gly Gly Gly Ser Gly Gly Gly Leu Glu His His His His His His His  
355 360 365

- 5 -

<210> 8  
<211> 537  
<212> PRT  
<213> Artificial Sequence  
5  
<220>  
<223> Description of Artificial Sequence:single-chain  
FkpA

10 <400> 8  
Met Ala Glu Ala Ala Lys Pro Ala Thr Thr Ala Asp Ser Lys Ala Ala  
1 5 10 15  
Phe Lys Asn Asp Asp Gln Lys Ser Ala Tyr Ala Leu Gly Ala Ser Leu  
15 20 25 30  
Gly Arg Tyr Met Glu Asn Ser Leu Lys Glu Gln Glu Lys Leu Gly Ile  
35 40 45  
20 Lys Leu Asp Lys Asp Gln Leu Ile Ala Gly Val Gln Asp Ala Phe Ala  
50 55 60  
Asp Lys Ser Lys Leu Ser Asp Gln Glu Ile Glu Gln Thr Leu Gln Ala  
65 70 75 80  
25 Phe Glu Ala Arg Val Lys Ser Ser Ala Gln Ala Lys Met Glu Lys Asp  
85 90 95  
30 Ala Ala Asp Asn Glu Ala Lys Gly Lys Glu Tyr Arg Glu Lys Phe Ala  
100 105 110  
Lys Glu Lys Gly Val Lys Thr Ser Ser Thr Gly Leu Val Tyr Gln Val  
115 120 125  
35 Val Glu Ala Gly Lys Gly Glu Ala Pro Lys Asp Ser Asp Thr Val Val  
130 135 140  
Val Asn Tyr Lys Gly Thr Leu Ile Asp Gly Lys Glu Phe Asp Asn Ser  
145 150 155 160  
40 Tyr Thr Arg Gly Glu Pro Leu Ser Phe Arg Leu Asp Gly Val Ile Pro  
165 170 175  
45 Gly Trp Thr Glu Gly Leu Lys Asn Ile Lys Lys Gly Lys Ile Lys  
180 185 190  
Leu Val Ile Pro Pro Glu Leu Ala Tyr Gly Lys Ala Gly Val Pro Gly  
195 200 205  
50 Ile Pro Pro Asn Ser Thr Leu Val Phe Asp Val Glu Leu Leu Asp Val  
210 215 220  
Lys Pro Ala Pro Lys Ala Asp Ala Lys Pro Glu Ala Asp Ala Lys Ala  
225 230 235 240  
55 Ala Asp Ser Ala Lys Lys Gly Gly Ser Gly Gly Ser Gly Gly

- 6 -

	245	250	255
	Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Gly Ser Gly Gly		
	260 265 270		
5	Gly Ser Gly Gly Ala Glu Ala Ala Lys Pro Ala Thr Thr Ala Asp		
	275 280 285		
	Ser Lys Ala Ala Phe Lys Asn Asp Asp Gln Lys Ser Ala Tyr Ala Leu		
10	290 295 300		
	Gly Ala Ser Leu Gly Arg Tyr Met Glu Asn Ser Leu Lys Glu Gln Glu		
	305 310 315 320		
15	Lys Leu Gly Ile Lys Leu Asp Lys Asp Gln Leu Ile Ala Gly Val Gln		
	325 330 335		
	Asp Ala Phe Ala Asp Lys Ser Lys Leu Ser Asp Gln Glu Ile Glu Gln		
	340 345 350		
20	Thr Leu Gln Ala Phe Glu Ala Arg Val Lys Ser Ser Ala Gln Ala Lys		
	355 360 365		
	Met Glu Lys Asp Ala Ala Asp Asn Glu Ala Lys Gly Lys Glu Tyr Arg		
25	370 375 380		
	Glu Lys Phe Ala Lys Glu Lys Gly Val Lys Thr Ser Ser Thr Gly Leu		
	385 390 395 400		
30	Val Tyr Gln Val Val Glu Ala Gly Lys Gly Glu Ala Pro Lys Asp Ser		
	405 410 415		
	Asp Thr Val Val Asn Tyr Lys Gly Thr Leu Ile Asp Gly Lys Glu		
	420 425 430		
35	Phe Asp Asn Ser Tyr Thr Arg Gly Glu Pro Leu Ser Phe Arg Leu Asp		
	435 440 445		
	Gly Val Ile Pro Gly Trp Thr Glu Gly Leu Lys Asn Ile Lys Gly		
40	450 455 460		
	Gly Lys Ile Lys Leu Val Ile Pro Pro Glu Leu Ala Tyr Gly Lys Ala		
	465 470 475 480		
45	Gly Val Pro Gly Ile Pro Pro Asn Ser Thr Leu Val Phe Asp Val Glu		
	485 490 495		
	Leu Leu Asp Val Lys Pro Ala Pro Lys Ala Asp Ala Lys Pro Glu Ala		
	500 505 510		
50	Asp Ala Lys Ala Ala Asp Ser Ala Lys Lys Gly Gly Ser Gly Gly		
	515 520 525		
	Gly Leu Glu His His His His His		
55	530 535		

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
3 January 2003 (03.01.2003)

PCT

(10) International Publication Number  
**WO 03/000878 A3**

(51) International Patent Classification<sup>7</sup>: C12N 15/62,  
A61K 38/00, C12N 5/10

(21) International Application Number: PCT/EP02/06957

(22) International Filing Date: 24 June 2002 (24.06.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
01 115 225.3 22 June 2001 (22.06.2001) EP  
01 120 939.2 31 August 2001 (31.08.2001) EP

(71) Applicant (*for DE only*): ROCHE DIAGNOSTICS GMBH [DE/DE]; Sandhofer Strasse 116, 68305 Mannheim (DE).

(71) Applicant (*for all designated States except DE*): E.HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstr. 124, CH-4070 Basel (CH).

(72) Inventors: SCHOLZ, Christian; Sindelsdorfer Strasse 35a, 82377 Penzberg (DE); ANDRES, Herbert; Kapellenwies 39, 82377 Penzberg (DE); FAATZ, Elke; Steinkreuz 1, 82386 Huglfing (DB); ENGEL, Alfred; Kustermannstrasse 3a, 82327 Tutzing (DE); SCHMITT, Urban; Waldstrasse 36, 82386 Oberhausen (DE).

BAZARSUREN, Ariuna; Birkenstrasse 29, 82377 Penzberg (DE); SCHAARSCHMIDT, Peter; Birkenstrasse 4, 82390 Ebering (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TI, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:  
— with international search report

(88) Date of publication of the international search report:  
9 October 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

A3  
WO 03/000878

(54) Title: USE OF FKBP CHAPERONES AS EXPRESSION TOOL

(57) Abstract: The present invention relates to the cloning and expression of foreign protein or polypeptides in bacteria such as *Escherichia coli*. In particular, this invention relates to expression tools comprising a FKBP-type peptidyl prolyl isomerase selected from the group consisting of FkbpA, SlyD, and trigger factor, methods of recombinant protein expression, the recombinant polypeptides thus obtained as well as to the use of such polypeptides.

## INTERNATIONAL SEARCH REPORT

Internal Application No  
PCT/EP 02/06957

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C12N15/62 A61K38/00 C12N5/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, FSTA, MEDLINE, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 207 420 B1 (DAVIS GREGORY D ET AL) 27 March 2001 (2001-03-27)  the whole document, in particular Fig. 2 and claim 13 ---	1-3, 9-15, 23-26
A	WO 00 20606 A (REIMANN HANSJOERG ; SCHIRMBECK REINHOLD (DE)) 13 April 2000 (2000-04-13)  the whole document ---	-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claims(s) or which is cited to establish the secondary character of another citation or other specific reason (as specified)
- \*O\* document relating to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and in conflict with the application but which does not understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or inventive if it is combined to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*Z\* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

23 January 2003

12/02/2003

Name and mailing address of the ISA  
European Patent Office, P.B. 5618 Patentlaan 2  
NL-2233 RA Rijswijk  
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl  
Fax: (+31-70) 340-3016

Authorized officer

Bassias, I

## INTERNATIONAL SEARCH REPORT

Internal Application No  
PCT/EP 02/06957

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>SPRENG S ET AL: "Construction of chromosomally encoded secreted hemolysin fusion proteins by use of mini-TnhyAs transposon."  FEMS MICROBIOLOGY LETTERS,  vol. 165, no. 1,  1 August 1998 (1998-08-01), pages 187-192,  XP002228406  ISSN: 0378-1097  the whole document, in particular Fig.2  (SS 4)</p> <p>-----</p>	
A	<p>SCHEIN C H: "PRODUCTION OF SOLUBLE RECOMBINANT PROTEINS IN BACTERIA"  BIO/TECHNOLOGY, NATURE PUBLISHING CO. NEW YORK, US,  vol. 7, no. 11,  1 November 1989 (1989-11-01), pages 1141-1149, XP000068927  ISSN: 0733-222X  the whole document</p> <p>-----</p>	
A	<p>NISHIHARA KAZUYO ET AL: "Overexpression of Trigger Factor prevent aggregation of recombinant proteins in Escherichia coli"  APPLIED AND ENVIRONMENTAL MICROBIOLOGY, WASHINGTON, DC, US,  vol. 66, no. 3, March 2000 (2000-03),  pages 884-889, XP002156141  ISSN: 0099-2240  the whole document</p> <p>-----</p>	

## **INTERNATIONAL SEARCH REPORT**

#### **Information on patent family members**

International Application No  
PCT/EP 02/06957

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
US 6207420	B1	27-03-2001	US	5989868 A	23-11-1999	
			AU	9482098 A	29-03-1999	
			WO	9913091 A1	18-03-1999	
WO 0020606	A	13-04-2000	WO	0020606 A1	13-04-2000	
			AU	9629498 A	26-04-2000	
			CA	2344993 A1	13-04-2000	
			EP	1117803 A1	25-07-2001	

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**